Results 201 to 210 of about 111,950 (304)

Use of Metronomic Chemotherapy in Hormone Receptor‐Positive/HER2‐Negative Metastatic Breast Cancer: A Retrospective Multicenter Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Purpose The optimal chemotherapy strategy after progression on cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) metastatic breast cancer remains a matter of controversy.
Lara Laini, Deborah Cosentini, Marta Laganà, Salvatore Grisanti, Giulia Scartabellati, Gianluca Fogazzi, Salvatore Strazzeri, Vito Amoroso, Greta Schivardi, Rebecca Pedersini, Alfredo Berruti, Antonella Turla   +11 more
wiley   +1 more source

The Significance of Somatic Variants Involved in the Development of Pancreatic Cancer in Patients with HBOC-Associated Germline Variants. [PDF]

Genes (Basel)
Uchiyama K, Nishikubo H, Sano T, Furukawa Y, Ma D, Imanishi D, Ishidate T, Gao H, Fan C, Yashiro M.   +9 more
europepmc   +1 more source

CCNE1: A Cell Cycle Regulator That Influences Tumor Progression

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACTCyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin‐dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S‐phase entry. In a broad spectrum of human malignancies—including breast, ovarian, gastric, and non‐small cell lung cancers ...
Liang Yan, Siyi Liu, Yanling Li, Qian He, Chen Long, Ning Tang, Yanhong Zhou   +6 more
wiley   +1 more source

PCNA-RECQL5-RPRD1B recruit repair components to stressed replication forks to promote survival of BRCA1-deficient cancer cells. [PDF]

Nucleic Acids Res
Tran MT, Williamson EA, Jaiswal AS, Arris D, Nguyen N, Carrillo A, Olsen S, Kong K, Shaheen M, Sadadeen D, Zhou D, Yuan Y, Syed S, Kwon Y, Salunkhe S, Sung P, Hromas R.   +16 more
europepmc   +1 more source

Exceptional Locoregional Pathological Response in Metastatic Triple‐Negative Breast Cancer Treated With Palliative Platinum‐Based Chemotherapy

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Locoregional pathological complete response with concurrent radiologic metabolic remission following palliative gemcitabine–carboplatin chemotherapy in young, low‐grade metastatic triple‐negative breast cancer patient suggests potential chemosensitivity in select advanced cases, warranting further clinical investigation.
Shristi Gupta, Abhisek Jha, Asmita Rayamajhi, Aron Neupane, Kshitiz Parajuli, Manash Jha   +5 more
wiley   +1 more source

Coincidence of L1 retrotransposition and DNA repair deficiency elicits synthetic lethality in S-phase mature neurons. [PDF]

iScience
Takahashi F, Yamamura T, Oki S.
europepmc   +1 more source

PD‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy in carefully selected ...
Wang Zhenyan, Wang Yan
wiley   +1 more source

Publisher Correction: A ubiquitin chain-feeding mechanism for BRCA1-A. [PDF]

Nat Commun
Murachelli AG, El Oualid F, Sixma TK.
europepmc   +1 more source

Association of HRD Score With Efficacy of Neoadjuvant Short‐Course Radiotherapy Plus Sequential Chemoimmunotherapy in pMMR Locally Advanced Rectal Cancer

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Homologous recombination deficiency (HRD) has been reported to be associated with increased sensitivity to platinum‐based treatment and radiotherapy in some solid tumors. Aim This study investigated the correlation between HRD score and treatment response to neoadjuvant short‐course radiotherapy combined with sequential chemotherapy
Xin Ran, He Xiao, Peng Zhou, Juan He, Mengyuan Si, Xiuqiong Chen, Xiaona Su, Zhuo Chen, Jia Du, Xiaoyan Dai, Xiao Yang, Haode Shen, Zongsheng He, Fan Li, Mengxia Li, Chuan Chen   +15 more
wiley   +1 more source

Combination olaparib and cyclophosphamide cancer therapy exacerbates ovarian reserve depletion in mice with conditional loss of <i>Brca1</i> in oocytes. [PDF]

Front Endocrinol (Lausanne)
Cao Y, Jalil ZA, Mu X, Stringer JM, Zerafa N, Winship AL, Hutt KJ.   +6 more
europepmc   +1 more source